[多发性硬化症免疫治疗下的结核病诊断与治疗：德国的现状与建议]
[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].
作者信息
Bittner Stefan, Engel Sinah, Lange Christoph, Weber Martin S, Haghikia Aiden, Luessi Felix, Korn Thomas, Klotz Luisa, Bayas Antonios, Paul Friedemann, Heesen Christoph, Stangel Martin, Wildemann Brigitte, Bergh Florian Then, Tackenberg Björn, Trebst Corinna, Warnke Clemens, Linker Ralf, Kerschensteiner Martin, Zettl Uwe, Tumani Hayrettin, Brück Wolfgang, Meuth Sven G, Kümpfel Tanja, Hemmer Bernhard, Wiendl Heinz, Gold Ralf, Zipp Frauke
机构信息
Klinik für Neurologie, Forschungszentrum Translationale Neurowissenschaften (FTN), Forschungszentrum für Immuntherapie (FZI), Rhine Main Neuroscience Network (rmn2), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.
Klinische Infektiologie, Medizinische Klinik, Forschungszentrum Borstel, Borstel, Deutschland.
出版信息
Nervenarzt. 2019 Dec;90(12):1245-1253. doi: 10.1007/s00115-019-0760-0.
After years of low incidence, a large increase of new tuberculosis (TB) cases has been reported in Germany since 2015. New immunotherapies for the treatment of multiple sclerosis (MS) are associated with a reduced immune competence and a potential increased risk for infections. Most neurologists lack specific experiences with TB infections. This article summarizes specific recommendations for the diagnostics and treatment of TB under MS immunotherapies with a focus on the situation in Germany. Due to low case numbers and little experience with the risk of TB under the new immunotherapies, the clinical competence network for MS (KKNMS) consensus recommendations have a low grade of evidence.
在多年低发病率之后，自2015年以来德国报告的新结核病（TB）病例大幅增加。用于治疗多发性硬化症（MS）的新型免疫疗法与免疫能力下降及感染风险潜在增加有关。大多数神经科医生缺乏结核病感染的具体经验。本文总结了在MS免疫疗法下结核病诊断和治疗的具体建议，重点关注德国的情况。由于病例数少且对新型免疫疗法下结核病风险的经验有限，MS临床能力网络（KKNMS）的共识建议证据等级较低。
Zotero 插件